Literature DB >> 25124061

Prevention of infections during primary immunodeficiency.

Claire Aguilar1, Marion Malphettes2, Jean Donadieu3, Olivia Chandesris4, Hélène Coignard-Biehler1, Emilie Catherinot5, Isabelle Pellier6, Jean-Louis Stephan7, Vincent Le Moing8, Vincent Barlogis9, Felipe Suarez4, Stéphane Gérart10, Fanny Lanternier1, Arnaud Jaccard11, Paul-Henri Consigny12, Florence Moulin13, Odile Launay14, Marc Lecuit1, Olivier Hermine4, Eric Oksenhendler2, Capucine Picard15, Stéphane Blanche16, Alain Fischer17, Nizar Mahlaoui16, Olivier Lortholary1.   

Abstract

Because infectious diseases are a major source of morbidity and mortality in the majority of patients with primary immunodeficiencies (PIDs), the application of a prophylactic regimen is often necessary. However, because of the variety of PIDs and pathogens involved, and because evidence is scarce, practices are heterogeneous. To homogenize practices among centers, the French National Reference Center for PIDs aimed at elaborating recommendations for anti-infectious prophylaxis for the most common PIDs. We performed a literature review of infectious complications and prophylactic regimens associated with the most frequent PIDs. Then, a working group including different specialists systematically debated about chemoprophylaxis, immunotherapy, immunization, and recommendations for patients. Grading of prophylaxis was done using strength of recommendations (decreasing from A to D) and evidence level (decreasing from I to III). These might help infectious diseases specialists in the management of PIDs and improving the outcome of patients with PIDs.
© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  immunizations; immunoglobulins; primary immunodeficiency; prophylaxis

Mesh:

Year:  2014        PMID: 25124061     DOI: 10.1093/cid/ciu646

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  18 in total

Review 1.  An Update on the Use of Immunomodulators in Primary Immunodeficiencies.

Authors:  Pandiarajan Vignesh; Amit Rawat; Surjit Singh
Journal:  Clin Rev Allergy Immunol       Date:  2017-04       Impact factor: 8.667

2.  Antibodies against Hepatitis A and Hepatitis B Virus in Intravenous Immunoglobulin Products.

Authors:  Soyoung Lee; Han Wool Kim; Kyung Hyo Kim
Journal:  J Korean Med Sci       Date:  2016-12       Impact factor: 2.153

3.  A cohort of French pediatric patients with primary immunodeficiencies: are patient preferences regarding replacement immunotherapy fulfilled in real-life conditions?

Authors:  Marlène Pasquet; Isabelle Pellier; Nathalie Aladjidi; Anne Auvrignon; Patrick Cherin; Pierre Clerson; Gregoire Jacques Noël Cozon; Roland Jaussaud; Boris Bienvenu; Cyrille Hoarau
Journal:  Patient Prefer Adherence       Date:  2017-07-10       Impact factor: 2.711

Review 4.  Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.

Authors:  Ciprian Tomuleasa; Shigeo Fuji; Cristian Berce; Anca Onaciu; Sergiu Chira; Bobe Petrushev; Wilhelm-Thomas Micu; Vlad Moisoiu; Ciprian Osan; Catalin Constantinescu; Sergiu Pasca; Ancuta Jurj; Laura Pop; Ioana Berindan-Neagoe; Delia Dima; Shigehisa Kitano
Journal:  Front Immunol       Date:  2018-02-19       Impact factor: 7.561

5.  Gastrointestinal disorders next to respiratory infections as leading symptoms of X-linked agammaglobulinemia in children - 34-year experience of a single center.

Authors:  Malgorzata Pac; Ewa A Bernatowska; Jarosław Kierkuś; Józef P Ryżko; Joanna Cielecka-Kuszyk; Teresa Jackowska; Bożena Mikołuć
Journal:  Arch Med Sci       Date:  2016-06-01       Impact factor: 3.318

6.  Anti-bacterial antibody and T cell responses in bronchiectasis are differentially associated with lung colonization and disease.

Authors:  Fathia G Jaat; Sajidah F Hasan; Audrey Perry; Sharon Cookson; Santosh Murali; John D Perry; Clare V Lanyon; Anthony De Soyza; Stephen M Todryk
Journal:  Respir Res       Date:  2018-05-30

7.  Managing Inflammatory Manifestations in Patients with Chronic Granulomatous Disease.

Authors:  Alessandra Magnani; Nizar Mahlaoui
Journal:  Paediatr Drugs       Date:  2016-10       Impact factor: 3.930

8.  Does the route of immunoglobin replacement therapy impact quality of life and satisfaction in patients with primary immunodeficiency? Insights from the French cohort "Visages".

Authors:  B Bienvenu; G Cozon; C Hoarau; M Pasquet; P Cherin; P Clerson; E Hachulla; J C Crave; J C Delain; R Jaussaud
Journal:  Orphanet J Rare Dis       Date:  2016-06-22       Impact factor: 4.123

Review 9.  Prevention of Infectious Complications in Patients With Chronic Granulomatous Disease.

Authors:  Maria A Slack; Isaac P Thomsen
Journal:  J Pediatric Infect Dis Soc       Date:  2018-05-09       Impact factor: 3.164

10.  Daily co-trimoxazole prophylaxis to prevent mortality in children with complicated severe acute malnutrition: a multicentre, double-blind, randomised placebo-controlled trial.

Authors:  James A Berkley; Moses Ngari; Johnstone Thitiri; Laura Mwalekwa; Molline Timbwa; Fauzat Hamid; Rehema Ali; Jimmy Shangala; Neema Mturi; Kelsey D J Jones; Hassan Alphan; Beatrice Mutai; Victor Bandika; Twahir Hemed; Ken Awuondo; Susan Morpeth; Samuel Kariuki; Gregory Fegan
Journal:  Lancet Glob Health       Date:  2016-06-02       Impact factor: 38.927

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.